{"id":"il2","safety":{"commonSideEffects":[{"rate":null,"effect":"Capillary leak syndrome"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Elevated liver enzymes"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-2 binds to IL-2 receptors on lymphocytes, promoting their proliferation, differentiation, and activation. This leads to enhanced cytotoxic T cell and NK cell-mediated killing of tumor cells. IL-2 has been used as an immunotherapeutic agent to boost endogenous anti-tumor immunity.","oneSentence":"IL-2 (interleukin-2) is a cytokine that activates and expands T cells and natural killer cells to enhance anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:17.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Metastatic renal cell carcinoma"}]},"trialDetails":[{"nctId":"NCT03686124","phase":"PHASE1, PHASE2","title":"ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2019-05-14","conditions":"Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult","enrollment":375},{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT02621021","phase":"PHASE2","title":"A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-04","conditions":"Melanoma","enrollment":170},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":"Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT02360579","phase":"PHASE2","title":"Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2015-09-24","conditions":"Metastatic Melanoma","enrollment":220},{"nctId":"NCT02557074","phase":"PHASE3","title":"TREg Activation in the Treatment of the PELADE (Alopecia Areata)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-12-15","conditions":"Alopecia Areata","enrollment":44},{"nctId":"NCT06730126","phase":"PHASE2","title":"Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-10","conditions":"Autoimmune Lymphoproliferative Syndrome","enrollment":15},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT07161999","phase":"PHASE2","title":"Study of COYA 302 for the Treatment of ALS","status":"RECRUITING","sponsor":"Coya Therapeutics","startDate":"2025-10-01","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":120},{"nctId":"NCT04629729","phase":"PHASE1","title":"FT819 in Subjects With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fate Therapeutics","startDate":"2021-07-12","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT06152809","phase":"PHASE1","title":"CIML NK Cells With Venetoclax for AML","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-20","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia","enrollment":10},{"nctId":"NCT06991361","phase":"PHASE1","title":"Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD","status":"NOT_YET_RECRUITING","sponsor":"Leslie Kean","startDate":"2026-05-01","conditions":"Graft Versus Host Disease (cGvHD)","enrollment":21},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT04977453","phase":"PHASE1, PHASE2","title":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2021-08-02","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer","enrollment":317},{"nctId":"NCT07115043","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-29","conditions":"Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)","enrollment":60},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT04695327","phase":"PHASE1","title":"TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy","status":"COMPLETED","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2021-01-11","conditions":"Solid Tumor","enrollment":32},{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT06917885","phase":"PHASE1","title":"CUE-102 in Recurrent Glioblastoma","status":"RECRUITING","sponsor":"David Reardon, MD","startDate":"2025-07-30","conditions":"Recurrent Glioblastoma, Glioblastoma, Glioma, Malignant","enrollment":18},{"nctId":"NCT05877599","phase":"PHASE1","title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-12","conditions":"Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma","enrollment":46},{"nctId":"NCT05290597","phase":"PHASE1","title":"A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2022-08-22","conditions":"Solid Malignancies or Lymphomas","enrollment":40},{"nctId":"NCT06961786","phase":"PHASE1","title":"TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2025-06-25","conditions":"Metastatic Melanoma","enrollment":9},{"nctId":"NCT06321484","phase":"PHASE1","title":"Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-09","conditions":"Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer","enrollment":18},{"nctId":"NCT07444437","phase":"PHASE2","title":"LM103 in Phase IIa Clinical Trial for Adjuvant Treatment in Patients With Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2026-02-26","conditions":"Non-Small Cell Lung Cancer","enrollment":45},{"nctId":"NCT07310784","phase":"PHASE2","title":"A Phase II Trial of LM103 in Advanced Melanoma","status":"RECRUITING","sponsor":"Suzhou BlueHorse Therapeutics Co., Ltd.","startDate":"2025-12-16","conditions":"Advanced Melanoma","enrollment":92},{"nctId":"NCT07443020","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors","status":"NOT_YET_RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT05081609","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ascendis Pharma Oncology Division A/S","startDate":"2022-01-11","conditions":"Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":320},{"nctId":"NCT04426669","phase":"PHASE1, PHASE2","title":"A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering","status":"COMPLETED","sponsor":"Intima Bioscience, Inc.","startDate":"2020-05-15","conditions":"Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract","enrollment":23},{"nctId":"NCT05566223","phase":"PHASE1, PHASE2","title":"CISH Inactivated TILs in the Treatment of NSCLC","status":"WITHDRAWN","sponsor":"Intima Bioscience, Inc.","startDate":"2023-02","conditions":"Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02340676","phase":"PHASE2","title":"A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-02","conditions":"Chronic Graft-versus-host-disease","enrollment":25},{"nctId":"NCT04052334","phase":"PHASE1","title":"Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-27","conditions":"Sarcoma","enrollment":9},{"nctId":"NCT01366092","phase":"PHASE2","title":"Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-07","conditions":"Chronic Graft-versus-host Disease","enrollment":35},{"nctId":"NCT01659151","phase":"PHASE2","title":"Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-08-03","conditions":"Metastatic Melanoma","enrollment":17},{"nctId":"NCT07389239","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-23","conditions":"Ovarian Cancer, Advanced Malignant Solid Tumor","enrollment":24},{"nctId":"NCT02559778","phase":"PHASE2","title":"Pediatric Precision Laboratory Advanced Neuroblastoma Therapy","status":"RECRUITING","sponsor":"Giselle Sholler","startDate":"2015-09","conditions":"Neuroblastoma","enrollment":500},{"nctId":"NCT05267626","phase":"PHASE1, PHASE2","title":"Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer","status":"RECRUITING","sponsor":"Aulos Bioscience, Inc.","startDate":"2022-04-04","conditions":"Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma","enrollment":159},{"nctId":"NCT07410494","phase":"PHASE1, PHASE2","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2026-02-01","conditions":"Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC)","enrollment":85},{"nctId":"NCT06237881","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-31","conditions":"Advanced Solid Tumor, Melanoma, Lung Neoplasms","enrollment":15},{"nctId":"NCT05155033","phase":"PHASE2","title":"Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-18","conditions":"Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma","enrollment":78},{"nctId":"NCT07288073","phase":"PHASE2","title":"TIL Therapy in cSCC and MCC","status":"RECRUITING","sponsor":"Karam Khaddour, MD, MS","startDate":"2026-02-10","conditions":"Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma","enrollment":14},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT07300475","phase":"PHASE1","title":"Cancer Immunotherapeutic (PCI) Strategy in Triple Negative Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2026-03-31","conditions":"Triple Negative Breast Cancer","enrollment":30},{"nctId":"NCT05493566","phase":"EARLY_PHASE1","title":"Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-11-01","conditions":"Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":15},{"nctId":"NCT07406724","phase":"PHASE2","title":"HS-IT101 Injection Versus Chemotherapy in the Treatment of Advanced Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Qingdao Sino-Cell Biomedicine Co., Ltd.","startDate":"2026-02-26","conditions":"Melanoma (Excluding Uveal Melanoma)","enrollment":90},{"nctId":"NCT06598371","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-21","conditions":"Select Advanced Solid Tumors","enrollment":141},{"nctId":"NCT05544448","phase":"NA","title":"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-02","conditions":"Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia","enrollment":67},{"nctId":"NCT02964078","phase":"PHASE2","title":"Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-04-25","conditions":"Kidney Cancer","enrollment":27},{"nctId":"NCT05479812","phase":"PHASE1","title":"Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab (Pembro) in Patients With Selected Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Werewolf Therapeutics, Inc.","startDate":"2022-05-20","conditions":"Metastatic Solid Tumor, Advanced Solid Tumor","enrollment":150},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT01937468","phase":"PHASE1","title":"Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-11","conditions":"Chronic Graft Versus Host Disease, Chronic GVHD, Complications of Organ Transplant Stem Cells","enrollment":25},{"nctId":"NCT05607095","phase":"PHASE1","title":"A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-11-01","conditions":"Uveal Melanoma, Melanoma, Metastatic Uveal Melanoma","enrollment":30},{"nctId":"NCT04263831","phase":"PHASE1, PHASE2","title":"Low Dose IL-2 for the Treatment of Crohn's Disease","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2021-03-11","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT03666000","phase":"PHASE1","title":"Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"Imugene Limited","startDate":"2019-03-11","conditions":"Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia","enrollment":135},{"nctId":"NCT07011004","phase":"PHASE1","title":"A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-05-30","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse","enrollment":18},{"nctId":"NCT04562129","phase":"PHASE2","title":"IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-09-24","conditions":"Melanoma Stage III, Melanoma Stage IV, Inoperable Disease","enrollment":29},{"nctId":"NCT06318871","phase":"EARLY_PHASE1","title":"Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-28","conditions":"Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma","enrollment":10},{"nctId":"NCT03474497","phase":"PHASE1, PHASE2","title":"UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Megan Daly, MD","startDate":"2019-05-20","conditions":"Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma","enrollment":18},{"nctId":"NCT07366658","phase":"PHASE1","title":"Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-02-20","conditions":"SCLC, Extensive Stage, Neuroendocrine Tumors","enrollment":9},{"nctId":"NCT05357027","phase":"PHASE1, PHASE2","title":"HPV16 E6 TCR T Cells for Cervical Carcinoma","status":"TERMINATED","sponsor":"TCRCure Biopharma Ltd.","startDate":"2022-08-10","conditions":"Cervical Carcinoma","enrollment":5},{"nctId":"NCT06334783","phase":"PHASE1","title":"TIL for Patients With Advanced Solid Tumor","status":"TERMINATED","sponsor":"Hervor Therapeutics","startDate":"2023-05-30","conditions":"Advanced Solid Tumor","enrollment":5},{"nctId":"NCT05868915","phase":"PHASE1","title":"HV-101 for Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hervor Therapeutics","startDate":"2023-08-04","conditions":"Advanced Solid Tumors","enrollment":1},{"nctId":"NCT07349160","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed Tumor-Infiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-10","conditions":"Advanced Solid Tumors","enrollment":36},{"nctId":"NCT07192900","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease","status":"RECRUITING","sponsor":"David Bartlett, MD","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT04855253","phase":"PHASE1, PHASE2","title":"Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL","status":"SUSPENDED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2021-06-09","conditions":"DLBCL, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma","enrollment":30},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT06640413","phase":"PHASE1","title":"A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors","status":"RECRUITING","sponsor":"Philogen S.p.A.","startDate":"2025-10-31","conditions":"FAP","enrollment":56},{"nctId":"NCT05989828","phase":"PHASE1","title":"A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"University of Southern California","startDate":"2024-12-17","conditions":"Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT02739412","phase":"PHASE2","title":"Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":6},{"nctId":"NCT07288203","phase":"PHASE2","title":"A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2025-11-28","conditions":"Melanoma (Skin Cancer), Unresectable Melanoma, Metastatic Melanoma","enrollment":100},{"nctId":"NCT06946225","phase":"PHASE1","title":"ACTengine® IMA203 Combined With mRNA-4203","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-07-25","conditions":"Cutaneous Melanoma, Synovial Sarcoma","enrollment":15},{"nctId":"NCT06255028","phase":"PHASE1","title":"A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Century Therapeutics, Inc.","startDate":"2025-02-06","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies","enrollment":6},{"nctId":"NCT05902520","phase":"PHASE1","title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgonOx, Inc.","startDate":"2023-06-19","conditions":"HNSCC, Melanoma, Gynecologic Cancer","enrollment":18},{"nctId":"NCT06236425","phase":"PHASE1","title":"TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-14","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT05628883","phase":"PHASE1","title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-11-22","conditions":"Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma","enrollment":17},{"nctId":"NCT06138587","phase":"PHASE1","title":"Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-01-24","conditions":"Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid","enrollment":15},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT05307874","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"ImCheck Therapeutics","startDate":"2022-05-04","conditions":"Solid Tumor, Adult","enrollment":56},{"nctId":"NCT06626256","phase":"PHASE1","title":"STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2025-12-05","conditions":"Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm","enrollment":""},{"nctId":"NCT04155710","phase":"PHASE1","title":"Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL","status":"COMPLETED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2020-02-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":7},{"nctId":"NCT06125197","phase":"PHASE1","title":"Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2024-07-23","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT07298551","phase":"","title":"Building an Assessment Model for Vitiligo Activity and Prognosis Using Peripheral Blood Cytokine Profiles","status":"NOT_YET_RECRUITING","sponsor":"Xijing Hospital","startDate":"2025-12-23","conditions":"Vitiligo","enrollment":125},{"nctId":"NCT04879277","phase":"NA","title":"Study of Low-grade Systemic Inflammation in Adult Patients With Phenylketonuria","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2021-05-26","conditions":"Phenylketonuria","enrollment":40},{"nctId":"NCT01319565","phase":"PHASE2","title":"Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-24","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":102},{"nctId":"NCT01701674","phase":"NA","title":"Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-10-09","conditions":"Metastatic Melanoma","enrollment":13},{"nctId":"NCT05802056","phase":"PHASE1","title":"Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-29","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":15},{"nctId":"NCT01005745","phase":"NA","title":"Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-10-20","conditions":"Metastatic Melanoma","enrollment":19},{"nctId":"NCT07030907","phase":"PHASE1","title":"A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Outpace Bio, Inc.","startDate":"2025-06-16","conditions":"Ovarian Cancer Recurrent, Ovarian Cancer, Platinum Resistant Ovarian Cancer","enrollment":30},{"nctId":"NCT05336409","phase":"PHASE1","title":"A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies","status":"TERMINATED","sponsor":"Century Therapeutics, Inc.","startDate":"2023-01-24","conditions":"R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT06413680","phase":"PHASE1, PHASE2","title":"A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-23","conditions":"Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors","enrollment":240},{"nctId":"NCT04009681","phase":"PHASE1, PHASE2","title":"A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)","status":"TERMINATED","sponsor":"Synthorx, Inc, a Sanofi company","startDate":"2019-06-20","conditions":"Metastasis","enrollment":175},{"nctId":"NCT03260504","phase":"PHASE1","title":"Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-08-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer","enrollment":6},{"nctId":"NCT07255664","phase":"PHASE1, PHASE2","title":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","status":"RECRUITING","sponsor":"Curacell Holding AB","startDate":"2025-11-13","conditions":"Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced","enrollment":12},{"nctId":"NCT05681780","phase":"PHASE1","title":"Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-03-10","conditions":"Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer","enrollment":13},{"nctId":"NCT05768347","phase":"PHASE1","title":"Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-10","conditions":"Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT03039673","phase":"PHASE2","title":"MIROCALS: Modifying Immune Response and OutComes in ALS","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-06-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":304},{"nctId":"NCT04303858","phase":"PHASE1","title":"A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-04","conditions":"Solid Tumors","enrollment":189},{"nctId":"NCT06961357","phase":"PHASE1, PHASE2","title":"Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-01-01","conditions":"Melanoma","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"DEHYDRATION"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"HAEMOGLOBIN DECREASED"},{"count":2,"reaction":"NAUSEA"},{"count":2,"reaction":"PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME"},{"count":2,"reaction":"VOMITING"},{"count":1,"reaction":"ABDOMINAL PAIN"},{"count":1,"reaction":"ALANINE AMINOTRANSFERASE INCREASED"},{"count":1,"reaction":"ALOPECIA"},{"count":1,"reaction":"ANAEMIA"}],"_approvalHistory":[],"publicationCount":60333,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Interleukin","Interleukin-2"],"phase":"phase_3","status":"active","brandName":"IL2","genericName":"IL2","companyName":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","companyId":"istituto-romagnolo-per-lo-studio-dei-tumori-dino-amadori-irst-s-r-l-irccs","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IL-2 (interleukin-2) is a cytokine that activates and expands T cells and natural killer cells to enhance anti-tumor immune responses. Used for Metastatic melanoma, Metastatic renal cell carcinoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}